Researchers have obtained molecular insights into a special process the SARS-CoV-2 relies on and shown that chemical compounds can inhibit it.
Inhibiting the process would significantly reduce viral replication in infected cells.
Viruses require the resources of an infected cell to replicate and then infect further cells, and transfer to other individuals. One essential step in the viral life cycle is production of new viral proteins based on the instructions in the viral RNA genome. Based on these construction plans, the cell’s own protein synthesis machine, called the ribosome, produces the viral proteins.
The dependence of SARS-CoV-2 on this ribosomal frameshifting event could be used to develop antiviral drugs.
In the absence of viral infection, the ribosome moves along the RNA in strictly defined steps, reading three letters of RNA at a time. This three-letter code defines the corresponding amino acid that attaching to the growing protein. It almost never happens that the ribosome slips one or two RNA letters forward or backward instead of following the regular three-letter steps. When such a slip of the ribosome occurs, it is called “a frameshift,” and it leads to incorrect reading of the genetic code.
Frameshifting almost never happens in our cells. It would lead to dysfunctional cellular proteins; however, certain viruses, such as coronaviruses and HIV, depend on a frameshifting event to regulate levels of viral proteins. For example, SARS-CoV-2—the virus that causes COVID-19—is critically dependent on frameshifting promoted by an unusual and intricate fold in the viral RNA.
Therefore, since frameshifting is essential for the virus but it almost never happens in our organism, any compound that inhibits frameshifting by targeting this RNA fold could potentially be useful as a drug to combat infection. However, so far, there is no information on how the viral RNA interacts with the ribosome to promote frameshifting, which would be important for drug development.
Now, researchers have, for the first time, managed to reveal the interactions between the viral genome and the ribosome during frameshifting.
Using sophisticated biochemical experiments, the researchers managed to capture the ribosome at the frameshifting site of the SARS-CoV-2 RNA genome. They could then study this molecular complex using cryo-electron microscopy.
The results provided a molecular description of the process at unprecedented detail and revealed a number of novel unanticipated features. The frameshifting event causes the usually dynamic ribosome machine to adopt a strained conformation, which helped provide one of the sharpest and most accurate images of a mammalian ribosome, visualized in the process of frameshifting while reading the information from the viral genome. The researchers then followed up on their structural findings with in vitro and in vivo experiments including exploring how this process can be targeted with chemical compounds.
“The results presented here on SARS-CoV-2 will also be useful for understanding the frameshifting mechanisms in other RNA viruses,” says Nenad Ban, professor for molecular biology at ETH Zurich and coauthor of the study.
The dependence of SARS-CoV-2 on this ribosomal frameshifting event could be used to develop antiviral drugs. Previous studies reported that several compounds are able to inhibit frameshifting in coronaviruses, however, this study now provides information about the effects of these compounds on levels of SARS-CoV-2 in infected cells.
In their experiments, both compounds reduced viral replication by three to four orders of magnitude and were not toxic for the treated cells. However, one of the two reduced viral replication by inhibiting ribosomal frameshifting, while the other might act through a different mechanism.
Although these compounds are currently not potent enough to be used as therapeutic drugs, this study demonstrates that inhibition of ribosomal frameshifting has a profound effect on viral replication, which paves the way for the development of better compounds. Due to the fact that all coronaviruses depend on this conserved frameshifting mechanism, a drug that targets this process may even be useful to treat infections by more distantly related coronaviruses.
“Our future work will focus on understanding the cellular defense mechanisms that suppress viral frameshifting, as this could be useful for development of small compounds with similar activity,” says Ban.
The study appears in Science.
Additional researchers from ETH Zurich and the Universities of Bern, Lausanne and Cork (in Ireland) contributed to the work.
Source: ETH Zurich